‘Chilling’ experimental drug returns as potential RA treatment


A phase II trial of an experimental drug that made headlines when it left human volunteers fighting for their lives is about to begin in Russia —  as a potential treatment for rheumatoid arthritis. The drug, then known as TGN1412, had caused six male volunteers in London to experience a ‘cytokine storm’ with devastating consequences. Fortunately ...


Already a member? Login to keep reading


OR
© 2017 the limbic